Sammy Farah
Chief Executive Officer at TURNSTONE BIOLOGICS CORP.
Net worth: - $ as of 2024-04-29
Profile
Sammy J.
Farah is currently the President, Chief Executive Officer & Director at Turnstone Biologics, Inc. He is also the President, Chief Executive Officer & Director at Turnstone Biologics Corp.
Additionally, he holds the position of Chief Executive Officer at Myst Therapeutics LLC.
Previously, Dr. Farah worked as an Investment Professional at Versant Venture Management LLC.
He also served as the Chief Business Officer at Immune Design Corp.
From 2011 to 2015, he was the President of Synthetic Genomics Vaccines, Inc.Dr. Farah obtained a doctorate degree from Stanford University.
He holds an MBA and a doctorate degree from the University of Pennsylvania.
He completed his undergraduate studies at the Massachusetts Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-18 | 0 ( -.--% ) | - $ | 2024-04-29 |
Sammy Farah active positions
| Companies | Position | Start |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Chief Executive Officer | 2015-09-30 |
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Chief Executive Officer | - |
Myst Therapeutics LLC
 Myst Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Myst Therapeutics LLC is a privately held, pre-clinical stage biotechnology company based in Glendale, CA. Myst Therapeutics LLC focuses on the development and commercialization of novel cancer immunotherapy products that utilize a patient's own immune system to treat solid tumors. Myst is dedicated to improving adoptive cell therapies, particularly neoantigen enriched T cell therapies for solid tumors. By combining methods of identifying neoantigen reactive T cells with their proprietary technologies and expertise in cell therapy development and manufacturing, Myst aims to rapidly advance and commercialize innovative therapies for a wide range of advanced solid tumors. The CEO of the company is Sammy J. Farah. Myst Therapeutics was acquired by Turnstone Biologics, Inc. on January 20, 2021. | Chief Executive Officer | - |
Former positions of Sammy Farah
| Companies | Position | End |
|---|---|---|
| Synthetic Genomics Vaccines, Inc. | President | 2015-09-30 |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Private Equity Analyst | 2010-05-30 |
| IMMUNE DESIGN CORP | Corporate Officer/Principal | - |
Training of Sammy Farah
| University of Pennsylvania | Doctorate Degree |
| Massachusetts Institute of Technology | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| TURNSTONE BIOLOGICS CORP. | Health Technology |
| Private companies | 5 |
|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
| Synthetic Genomics Vaccines, Inc. | |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Health Technology |
Myst Therapeutics LLC
Myst Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Myst Therapeutics LLC is a privately held, pre-clinical stage biotechnology company based in Glendale, CA. Myst Therapeutics LLC focuses on the development and commercialization of novel cancer immunotherapy products that utilize a patient's own immune system to treat solid tumors. Myst is dedicated to improving adoptive cell therapies, particularly neoantigen enriched T cell therapies for solid tumors. By combining methods of identifying neoantigen reactive T cells with their proprietary technologies and expertise in cell therapy development and manufacturing, Myst aims to rapidly advance and commercialize innovative therapies for a wide range of advanced solid tumors. The CEO of the company is Sammy J. Farah. Myst Therapeutics was acquired by Turnstone Biologics, Inc. on January 20, 2021. | Commercial Services |
- Stock Market
- Insiders
- Sammy Farah
